Logo-apb
Adv Pharm Bull. 2024;14(2): 262-265. doi: 10.34172/apb.2024.040
PMID: 39206389        PMCID: PMC11347740

Editorial

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression

Amr Ahmed 1 ORCID, Maher Monir. Akl 2 * ORCID

Cited by CrossRef: 0


1- Akl M, Ahmed A. Targeting the feminized nature of prostate cancer exploring estrogen-driven metabolic reprogramming and its therapeutic intervention: A narrative review. Sibirskij nauchnyj medicinskij zhurnal. 2026;45(6):18 [Crossref]
2- Lisco G, De Tullio A, Disoteo O, Armigliato M, Guastamacchia E, Marucci S, De Pergola G, Papini E, Chianelli M, Frasoldati A, De Geronimo V, Triggiani V. Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists. Diabetes Metabolism Res. 2025;41(6) [Crossref]